Herpes Zoster (HZ), Post Herpetic Neuralgia (PHN)
Conditions
Brief summary
Post-herpetic neuralgia (PHN) is the most significant complication of herpes zoster caused by reactivation of latent Varicella-Zoster virus (VZV). PHN is characterized by neuropathic pain lasting beyond the resolution of the rashes. Post herpetic neuralgia (PHN) represents a potentially debilitating and often undertreated form of neuropathic pain that disproportionately affects vulnerable populations, including the elderly and the immunocompromised. PHN pain is typically localized, unilateral and chronic, but may be constant, intermittent, spontaneous and/or evoked. PHN is likely to interfere with sleep and daily activities. Pregabalin is a gabapentinoid licenced for treatment of neurological disorders. It is one of the earlier drugs approved by the US Food and Drug Administration (2004) for the treatment of painful diabetic neuropathy and postherpetic neuralgia (PHN). Lacosamide (LCM) was approved in 2008 in the European Union and in the United States as adjunctive therapy for the treatment of focal-onset seizures with or without secondary generalization in adults and adolescents with epilepsy. Its efficacy has also been proven in neuropathic pain. Although Pregabalin and Lacosamide have proven effective in various neuropathic pain disorder, comparative studies specifically for PHN remain scarce. This study aims to compare the efficacy of Pregabalin and Lacosamide in PHN patients, addressing the current gap in literature and providing clinically relevant insights to optimize treatment selection.
Interventions
DRUGPregabalin
o Group A will receive Cap Pregabalin 150mg oral OD for 4 weeks
DRUGLacosamide
o Group B will receive Tab Lacosamide 100mg oral BD for 4 weeks
Sponsors
CMH Kharian Medical College
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
No
Inclusion criteria
* Diagnosed cases of herpes zoster suffering from postherpetic neuralgia * Ages: 18 to 50 * Both male and female
Exclusion criteria
* Lack of consent * Patient already taking pain killers for post herpetic neuralgia * Patients suffering from other systemic illness
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Visual Analog Scale | 4 weeks | Pain intensity will be measured before and after treatment with help of Visual Analog Scale. |
Countries
Pakistan
Contacts
Primary ContactMushayada Irshad, MBBS, MPhil Pharmacology
Backup ContactMuhammad Waseem Shahid, MBBS, FCPS Dermatology
Outcome results
None listed